Ongoing Clinical Trials in Urology

**Urological Oncology-Principal Investigator: Katie S Murray, DO, MS, FACS**

- **Prostate Cancer**
  - SWOG1802: Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
  - Alliance A222001: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Oxybutynin versus Placebo for the Treatment of Hot Flashes in Men Receiving Androgen Deprivation Therapy

- **Bladder Cancer**
  - Alliance A031803: Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
  - Alliance A031701: A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for those Patients whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations.

**Genitourinary Medical Oncology-Principal Investigator: Naha Kushal, MD, (Medical Oncology)**

- **Prostate Cancer**
  - Alliance A031902: A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer (CASPAR)

- **Bladder Cancer**
  - Alliance A032002: Phase II Randomized Trial of Atezolizumab Versus Atezolizumab and Radiation Therapy for Platinum Ineligible/Refractory Metastatic Urothelial Cancer (ART)
  - SWOG 1937: A Phase III Randomized Trial of Eribulin with or without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy

- **Kidney Cancer**
  - Alliance A031704: PD-inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab in Metastatic Untreated REnal Cell CancEr [PDIGREE]

**Genitourinary Radiation Oncology-Principal Investigator: Gregory Biedermann, MD (Radiation Oncology)**

- **Prostate Cancer**
NRG-GU009: Parallel Phase III Randomized Trials For High Risk Prostate Cancer Evaluating De-Intensification For Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (Predict-RT*)

NRG-GU010: Parallel Phase III Randomized Trials of Genomic Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)

**Benign Urology-Principal Investigator: Katie S Murray, DO, MS, FACS**

- **Robotic Surgery-Investigator Initiated**
  - A Prospective, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial Evaluating the Use of Perioperative Intravenous Lidocaine Infusion to Decrease Pain Scores and Opioid Consumption after Robotic-Assisted Prostatectomy and Robotic-Assisted Partial Nephrectomy

- **Kidney Stone Surgery (Ureteroscopy)-Investigator Initiated**
  - Perioperative Pregabalin as Part of a Multimodal Treatment Plan for Ureteral Stent Symptoms after Ureteroscopy